C4 Therapeutics, Inc.

NasdaqGS:CCCC Stock Report

Mkt Cap: US$400.0m

C4 Therapeutics Future Growth

How is C4 Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


0.7%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

NasdaqGS:CCCC - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202538-305-158-2007
12/31/202429-227-159-17510
12/31/202335-179-128-14912
9/30/202248-107-107-102N/A
6/30/202250-99-94-93N/A
3/31/202246-95-90-89N/A
12/31/202146-84-88-87N/A
9/30/202134-80-84-83N/A
6/30/202134-82-81-79N/A
3/31/202134-73-76-76N/A
12/31/202033-66-68-67N/A
9/30/202033-67-56-56N/A
6/30/202030-52-50-49N/A
3/31/202024-4712N/A
12/31/201921-435456N/A
12/31/201819-24-20-17N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CCCC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CCCC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CCCC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CCCC's revenue (61.3% per year) is forecast to grow faster than the US market (6.9% per year).

High Growth Revenue: CCCC's revenue (61.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CCCC is forecast to be unprofitable in 3 years.


Discover growth companies